Use of Daclizumab for the Prevention of Allograft Rejection in Pediatric Heart Transplant Patients
Status:
Terminated
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This protocol is designed to obtain information on the drug levels, metabolism, and safety of
daclizumab (Zenapax(R)) in children and adolescents undergoing cardiac transplantation. In
addition to the drug safety and metabolism information, the number and severity of rejection
episodes in patients undergoing cardiac transplantation using the standard immunosuppressive
drugs plus daclizumab will be compared with patients who have previously undergone cardiac
transplantation at the Baylor College of Medicine and received the same standard
immunosuppressive drugs without daclizumab.